Antibody to the Filarial Antigen Wb123 Reflects Reduced Transmission and Decreased Exposure in Children Born following Single Mass Drug Administration (MDA)

PLoS Neglected Tropical Diseases

Volumn 6, Issue 12, 2012, Pages

  Steel, Cathy ^a   Kubofcik, Joseph ^a   Ottesen, Eric A ^b   Nutman, Thomas B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Lymphatic Filariasis Support Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIETHYLCARBAMAZINE; IMMUNOGLOBULIN G4; PARASITE ANTIGEN; UNCLASSIFIED DRUG; WB123 ANTIGEN;

ADOLESCENT; ADULT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BANCROFTIAN FILARIASIS; CHILD; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOPRECIPITATION; INFANT; MAJOR CLINICAL STUDY; MASS SCREENING; MICROFILARIASIS; POPULATION DYNAMICS; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; SINGLE DRUG DOSE; WUCHERERIA BANCROFTI;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTHELMINTICS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CHILD; CHILD, PRESCHOOL; CLINICAL LABORATORY TECHNIQUES; DIETHYLCARBAMAZINE; FEMALE; FILARIASIS; HUMANS; IMMUNOPRECIPITATION; INFANT; MALE; MIDDLE AGED; PARASITOLOGY; POLYNESIA; SEROEPIDEMIOLOGIC STUDIES; WUCHERERIA BANCROFTI; YOUNG ADULT;

EID: 84872049427     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001940     Document Type: Article

References (27)

1. WHO (2011) Global Programme to Eliminate Lymphatic Filariasis: progress report on mass drug administration, 2010. Weekly epidemiological record 86: 377-388.
2. Ottesen EA, Hooper PJ, Bradley M, Biswas G, (2008) The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2: e317.
3. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA, (2010) The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl Trop Dis 4: e708.
4. Weil GJ, Lammie PJ, Weiss N, (1997) The ICT Filariasis Test: A rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today 13: 401-404.
5. Lammie PJ, Weil G, Noordin R, Kaliraj P, Steel C, et al. (2004) Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis- a multicenter trial. Filaria J 3: 9.
6. Ottesen EA, (2006) Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol 61: 395-441.
7. Moss DM, Priest JW, Boyd A, Weinkopff T, Kucerova Z, et al. (2011) Multiplex bead assay for serum samples from children in haiti enrolled in a drug study for the treatment of lymphatic filariasis. Am J Trop Med Hyg 85: 229-237.
8. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, et al. (2006) Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992-999.
9. Weil GJ, Curtis KC, Fischer PU, Won KY, Lammie PJ, et al. (2010) A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop.
10. Abdul Rahman R, Hwen-Yee C, Noordin R, (2007) Pan LF-ELISA using BmR1 and BmSXP recombinant antigens for detection of lymphatic filariasis. Filaria J 6: 10.
11. Pandiaraja P, Arunkumar C, Hoti SL, Rao DN, Kaliraj P, (2010) Evaluation of synthetic peptides of WbSXP-1 for the diagnosis of human lymphatic filariasis. Diagn Microbiol Infect Dis 68: 410-415.
12. Krushna NS, Shiny C, Dharanya S, Sindhu A, Aishwarya S, et al. (2009) Immunolocalization and serum antibody responses to Brugia malayi pepsin inhibitor homolog (Bm-33). Microbiol Immunol 53: 173-183.
13. Helmy H, Weil GJ, Ellethy AS, Ahmed ES, Setouhy ME, et al. (2006) Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans R Soc Trop Med Hyg 100: 656-662.
14. Weil GJ, Kastens W, Susapu M, Laney SJ, Williams SA, et al. (2008) The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis 2: e344.
15. Gass K, Beau de Rochars MV, Boakye D, Bradley M, Fischer PU, et al. (2012) A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl Trop Dis 6: e1479.
16. Burbelo PD, Ching KH, Bush ER, Han BL, Iadarola MJ, (2010) Antibody-profiling technologies for studying humoral responses to infectious agents. Expert Rev Vaccines 9: 567-578.
17. Ottesen EA, Weller PF, Lunde MN, Hussain R, (1982) Endemic filariasis on a Pacific Island. II. Immunologic aspects: immunoglobulin, complement, and specific antifilarial IgG, IgM, and IgE antibodies. Am J Trop Med Hyg 31: 953-961.
18. Steel C, Guinea A, Ottesen EA, (1996) Evidence for protective immunity to bancroftian filariasis in the Cook Islands. J Infect Dis 174: 598-605.
19. Steel C, Ottesen EA, (2001) Evolution of immunologic responsiveness of persons living in an area of endemic bancroftian filariasis: a 17-year follow-up. J Infect Dis 184: 73-79.
20. Weller PF, Ottesen EA, Heck L, Tere T, Neva FA, (1982) Endemic filariasis on a Pacific island. I. Clinical, epidemiologic, and parasitologic aspects. Am J Trop Med Hyg 31: 942-952.
21. Lal RB, Ottesen EA, (1988) Enhanced diagnostic specificity in human filariasis by IgG4 antibody assessment. J Infect Dis 158: 1034-1037.
22. WHO (2011) Global programme to eliminate lymphatic filariasis- monitoring and epidemiological assessment of mass drug administration: a manual for national elimination programmes. WHO/HTM/NTD/PCT; Geneva, Switzerland 4: 79.
23. Liang JL, King JD, Ichimori K, Handzel T, Pa'au M, et al. (2008) Impact of five annual rounds of mass drug administration with diethylcarbamazine and albendazole on Wuchereria bancrofti infection in American Samoa. Am J Trop Med Hyg 78: 924-928.
24. Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, et al. (2010) Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission. PLoS Negl Trop Dis 4: e696.
25. Tisch DJ, Bockarie MJ, Dimber Z, Kiniboro B, Tarongka N, et al. (2008) Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation. Am J Trop Med Hyg 78: 289-293.
26. Singh A, Kamal S, Rathaur S, (2010) Filarial selenium glutathione peroxidase: a probable immunodiagnostic marker for lymphatic filariasis. Trans R Soc Trop Med Hyg 104: 524-528.
27. Steel C, Ottesen EA, Weller PF, Nutman TB, (2001) Worm burden and host responsiveness in Wuchereria bancrofti infection: use of antigen detection to refine linear assessments from the South Pacific. Am J Trop Med Hyg 65: 498-503.